Zai Lab (ZLAB) Cash from Financing Activities (2018 - 2026)
Zai Lab (ZLAB) posted Cash from Financing Activities of $5.6 million for Q1 2026, up 1396.05% sequentially from -$430000.0 in Q4 2025, and down 87.08% YoY from $43.1 million in Q1 2025.
Zai Lab (ZLAB) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Zai Lab has reported Cash from Financing Activities for 9 years, with the latest figure at $5.6 million in Q1 2026.
- Quarterly Cash from Financing Activities fell 87.08% year-over-year to $5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.8 million (down 89.93% YoY) and the FY2025 annual result came in at $72.4 million, down 79.32% from the prior year.
- Cash from Financing Activities advanced to $5.6 million in Q1 2026 per ZLAB's latest filing, from -$430000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $237.8 million in Q4 2024 and troughed at -$3.9 million in Q1 2023.
- A 5-year average of $24.7 million and a median of $709000.0 in 2022 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities plunged 1606.2% in 2023, then jumped 60411.96% in 2024.
- Over 5 years, Cash from Financing Activities stood at -$199000.0 in 2022, then surged by 297.49% to $393000.0 in 2023, then surged by 60411.96% to $237.8 million in 2024, then tumbled by 100.18% to -$430000.0 in 2025, then jumped by 1396.05% to $5.6 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $5.6 million, -$430000.0, and $20.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Zai Lab | 2.91 Bn | 2.20 Bn | 58.15 Mn | 18.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.71 Mn |
| Jun 30, 2026 | 18.71 Mn |
| Mar 31, 2026 | 5.57 Mn |
| Mar 31, 2026 | 5.57 Mn |
| Dec 31, 2025 | -430,000.00 |
| Dec 31, 2025 | -430,000.00 |
| Sep 30, 2025 | 20.79 Mn |
| Sep 30, 2025 | 20.79 Mn |
| Jun 30, 2025 | 8.85 Mn |
| Jun 30, 2025 | 8.85 Mn |
| Mar 31, 2025 | 43.14 Mn |
| Mar 31, 2025 | 43.14 Mn |
| Dec 31, 2024 | 237.81 Mn |
| Dec 31, 2024 | 237.81 Mn |
| Sep 30, 2024 | 42.21 Mn |
| Sep 30, 2024 | 42.21 Mn |
| Jun 30, 2024 | 22.32 Mn |
| Jun 30, 2024 | 22.32 Mn |
| Mar 31, 2024 | 47.55 Mn |
| Mar 31, 2024 | 47.55 Mn |